Cargando…
Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?
STUDY QUESTION: Is it possible to reduce the cost of GnRH agonist treatment for endometriosis by using non-standard dosing regimens? SUMMARY ANSWER: An extended-interval dosing regimen of a 3.75 mg depot formulation of triptorelin injected every 6 weeks instead of every 4 weeks reduces the cost by o...
Autores principales: | Vercellini, Paolo, Bandini, Veronica, Buggio, Laura, Barbara, Giussy, Berlanda, Nicola, Dridi, Dhouha, Frattaruolo, Maria Pina, Somigliana, Edgardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067151/ https://www.ncbi.nlm.nih.gov/pubmed/37016694 http://dx.doi.org/10.1093/hropen/hoad008 |
Ejemplares similares
-
The Subjective Experience of Dyspareunia in Women with Endometriosis: A Systematic Review with Narrative Synthesis of Qualitative Research
por: Facchin, Federica, et al.
Publicado: (2021) -
Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review
por: Donnez, Jacques, et al.
Publicado: (2021) -
Self-management and psychological-sexological interventions in patients with endometriosis: strategies, outcomes, and integration into clinical care
por: Buggio, Laura, et al.
Publicado: (2017) -
GnRH agonists in the treatment of symptomatic endometriosis: a review
por: Surrey, Eric S.
Publicado: (2022) -
Gonadotropin-Releasing Hormone (GnRH)/GnRH Receptors and Their Role in the Treatment of Endometriosis
por: Resta, Christina, et al.
Publicado: (2023)